41,571 Shares in Gilead Sciences, Inc. $GILD Acquired by Commerzbank Aktiengesellschaft FI

Commerzbank Aktiengesellschaft FI acquired a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the second quarter, Holdings Channel.com reports. The fund acquired 41,571 shares of the biopharmaceutical company’s stock, valued at approximately $5,252,000.

Several other large investors have also recently added to or reduced their stakes in GILD. Norges Bank acquired a new stake in shares of Gilead Sciences during the 4th quarter valued at $2,617,152,000. Boston Partners acquired a new position in shares of Gilead Sciences in the fourth quarter worth $517,808,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of Gilead Sciences in the second quarter worth $398,905,000. Bank of America Corp DE raised its holdings in shares of Gilead Sciences by 15.2% during the fourth quarter. Bank of America Corp DE now owns 23,121,620 shares of the biopharmaceutical company’s stock worth $2,837,948,000 after acquiring an additional 3,046,688 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in shares of Gilead Sciences by 1.8% during the fourth quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company’s stock worth $14,863,487,000 after acquiring an additional 2,113,692 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analyst Ratings Changes

GILD has been the topic of a number of recent research reports. Cantor Fitzgerald restated an “overweight” rating and issued a $155.00 target price on shares of Gilead Sciences in a research note on Wednesday, August 5th. Rothschild & Co Redburn cut their price target on Gilead Sciences from $170.00 to $167.00 in a research note on Monday, May 11th. Truist Financial reduced their price target on Gilead Sciences from $157.00 to $156.00 and set a “buy” rating for the company in a report on Tuesday, July 7th. Daiwa Securities Group dropped their price objective on Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating on the stock in a report on Tuesday, May 19th. Finally, Morgan Stanley cut their price objective on shares of Gilead Sciences from $166.00 to $165.00 and set an “overweight” rating on the stock in a research report on Monday, July 27th. Twenty-four research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, Gilead Sciences presently has an average rating of “Moderate Buy” and an average price target of $158.04.

Insider Buying and Selling

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $123.92, for a total transaction of $371,760.00. Following the completion of the sale, the insider owned 124,234 shares of the company’s stock, valued at $15,395,077.28. This represents a 2.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $130.31, for a total value of $1,954,650.00. Following the transaction, the chief executive officer owned 592,133 shares in the company, valued at approximately $77,160,851.23. This trade represents a 2.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 51,000 shares of company stock worth $6,568,860. 0.30% of the stock is currently owned by insiders.

Gilead Sciences Trading Up 0.4%

Gilead Sciences stock opened at $138.92 on Tuesday. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09. The company has a market capitalization of $172.25 billion, a price-to-earnings ratio of -52.03 and a beta of 0.32. Gilead Sciences, Inc. has a one year low of $108.46 and a one year high of $157.29. The company’s fifty day moving average price is $130.33 and its two-hundred day moving average price is $136.43.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, topping analysts’ consensus estimates of ($7.25) by $0.50. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The company had revenue of $7.80 billion during the quarter, compared to analysts’ expectations of $7.40 billion. During the same quarter in the previous year, the firm earned $2.01 earnings per share. The business’s quarterly revenue was up 10.6% compared to the same quarter last year. On average, analysts forecast that Gilead Sciences, Inc. will post -0.53 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th will be paid a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date of this dividend is Tuesday, September 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently -122.85%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.